Otto Metzger

8.8k citations

117 papers · 4.8k indexed · 2 hit papers · h-index 30

Impact in

Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
Cancer Research top 0.5%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics

Papers in

Cancer Research 58
- Breast Cancer Treatment Studies 55
Oncology 77
- HER2/EGFR in Cancer Research 51
- Cancer Treatment and Pharmacology 27
- Peptidase Inhibition and Analysis 9

Co-authors: Eric P. Winer Evandro de Azambuja Martine Piccart Kamal S. Saini Ian E. Krop Sherene Loi Giuseppe Viale Michail Ignatiadis
Journals: Journal of Clinical Oncology (25 papers)Cancer Research (14 papers)Annals of Oncology (9 papers)Breast Cancer Research and Treatment (5 papers)The Breast (4 papers)
Partner nations: United States Belgium Italy

In The Last Decade

Otto Metzger

105 papers receiving 4.7k citations

Hit Papers

align trajectories log scale

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial 2018 · 516 citations

Peers

Countries citing papers authored by Otto Metzger

Since Specialization

Citations

This map shows the geographic impact of Otto Metzger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Otto Metzger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Otto Metzger more than expected).

Fields of papers citing papers by Otto Metzger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Otto Metzger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Otto Metzger. The network helps show where Otto Metzger may publish in the future.

Co-authors

The 25 scholars most cited alongside Otto Metzger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Otto Metzger Line = papers co-authored together Otto Metzger links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Adjuvant Dose-Dense Chemotherapy in Hormone Receptor–Positive Breast Cancer Journal of Clinical Oncology ·Otto Metzger, Karla V. Ballman, Jordan D. Campbell, Minetta C. Liu, Jennifer A. Ligibel, Mark A. Watson, Eveline Chen, Lili Du, Daniel G. Stover, Lisa A. Carey, Ann H. Partridge, Jeffrey Kirshner, Hyman B. Muss, Clifford A. Hudis, Eric P. Winer, Larry Norton, W. Fraser Symmans	2025	1
2	Surgeon Perspectives on Axillary Management Following Neoadjuvant Endocrine Therapy: Results from a Qualitative Substudy of the PELOPS Trial Annals of Surgical Oncology ·Anna Weiss, Anna Revette, Brett Nava-Coulter, Elizabeth A. Mittendorf, Otto Metzger, Tari A. King	2025	0
3	Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial Annals of Surgical Oncology ·Anna Weiss, Qingchun Jin, Nabihah Tayob, Eileen Wrabel, Michelle K. DeMeo, Jamie Carter, Michael Constantine, Meredith Faggen, Caroline Block, Mary Anne Fenton, K. M. Steve Lo, Thomas H. Openshaw, Denise A. Yardley, Laura C. Kennedy, Isabelle Bedrosian, Elizabeth A. Mittendorf, Rinath Jeselsohn, Otto Metzger, Tari A. King	2025	0
4	Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium The Lancet Regional Health - Europe ·Maria Alice Franzoi, Arlindo R. Ferreira, Antoine Lemaire, Joseph Rodriguez, Jessica Grosjean, Joana Ribeiro, Laura Polastro, Thomas Grellety, Xavier Artignan, Katell Le Dû, Martina Pagliuca, É. Nouhaud, M. Autheman, Fabrice André, Ethan Basch, Otto Metzger, Charles Ferté, Mario Di Palma, Florian Scotté, Inês Vaz-Luís	2024	15
5	Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer ESMO Open ·Albert Grinshpun, Shan Ren, Noah Graham, M.K. DeMeo, Eileen Wrabel, John A. Carter, Nabihah Tayob, Alyssa Pereslete, E. Hamilton, Dejan Juric, EL Mayer, SM Tolaney, Ian E. Krop, Otto Metzger	2024	4
6	Temporal and spatial topography of cell proliferation in cancer Nature Cell Biology ·Giorgio Gaglia, Sheheryar Kabraji, Danae Rammos, Yang Dai, Ana Verma, Shu Wang, Caitlin E. Mills, Mirra Chung, Johann S. Bergholz, Shannon Coy, Jia‐Ren Lin, Rinath Jeselsohn, Otto Metzger, Eric P. Winer, Deborah Dillon, Jean J. Zhao, Peter K. Sorger, Sandro Santagata	2022	31
7	Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma Clinical Cancer Research ·Raquel Nunes, Tal Sella, Kai Treuner, Jennifer M. Atkinson, Jenna Wong, Yi Zhang, Pedro Exman, David J. Dabbs, Andrea L. Richardson, Catherine A. Schnabel, Dennis C. Sgroi, Steffi Oesterreich, Ashley Cimino‐Mathews, Otto Metzger	2021	13
8	Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab Cancer Discovery ·Otto Metzger, Giuseppe Viale, Shayna Stein, Lorenzo Trippa, Denise A. Yardley, Ingrid A. Mayer, Vandana G. Abramson, Carlos L. Arteaga, Laura M. Spring, Adrienne G. Waks, Eileen Wrabel, Michelle K. DeMeo, Aditya Bardia, Patrizia Dell’Orto, Leila Russo, Tari A. King, Kornélia Polyák, Franziska Michor, Eric P. Winer, Ian E. Krop	2021	148
9	42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC) Annals of Oncology ·Otto Metzger, Chiara Lambertini, IE Krop, Gail D. Lewis Phillips, Charles M. Perou, F. Symmans, Ignacio Melero, Nadia Harbeck, EP Winer, S-A. Im, Carlos H. Barrios, Hervé Bonnefoi, Julie R. Gralow, Peter Ellis, Lorenzo Gianni, Masakazu Toi, Sandra M. Swain, Thomas Boulet, Chunyan Song, SL de Haas	2021	3
10	A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer Breast Cancer Research and Treatment ·Otto Metzger, Anita Giobbie‐Hurder, Nancy U. Lin, Meredith Faggen, Steven E. Come, Thomas H. Openshaw, Michael Constantine, Jeanna Walsh, Rachel A. Freedman, Bryan P. Schneider, Harold J. Burstein, Erica L. Mayer	2020	6
11	PALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer Annals of Oncology ·Erica L. Mayer, Angela DeMichele, Georg Pfeiler, W Barry, Otto Metzger, Priya Rastogi, F. Symmans, Harold J. Burstein, Kathy D. Miller, Sibylle Loibl, Sabine Schmatloch, Theodora Goulioti, Dimitrios Zardavas, Christian Fesl, María Koehler, Cynthia Huang Bartlett, Xin Huang, Martine Piccart, Eric P. Winer, Michael Gnant	2017	7
12	Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis Breast Cancer Research and Treatment ·Antonio Di Meglio, Rachel A. Freedman, Nancy U. Lin, William T. Barry, Otto Metzger, Nancy L. Keating, Tari A. King, Mario Roberto Sertoli, Francesco Boccardo, Eric P. Winer, Inês Vaz-Luís	2016	31
13	CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01) The Lancet Oncology ·Bernhard C. Pestalozzi, Eileen Holmes, Evandro de Azambuja, Otto Metzger, Laurence Hogge, Matt Scullion, István Láng, Andrew Wardley, Mikhail Lichinitser, Roberto Sánchez, Volkmar Müller, David Dodwell, Richard D. Gelber, Martine Piccart, David Cameron	2013	142
14	Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer Cancer Treatment Reviews ·Kamal S. Saini, Sherene Loi, Evandro de Azambuja, Otto Metzger, Monika Lamba Saini, Michail Ignatiadis, Janet Dancey, Martine Piccart	2013	311
15	Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial Journal of Clinical Oncology ·Otto Metzger, Marion Procter, Evandro de Azambuja, Brian Leyland‐Jones, Richard D. Gelber, Mitch Dowsett, Sherene Loi, Kamal S. Saini, David Cameron, Michael Untch, Ian Smith, Luca Gianni, José Baselga, Christian Jackisch, Richard H. Bell, Christos Sotiriou, Giuseppe Viale, Martine Piccart	2013	30
16	Pertuzumab in metastatic breast cancer: unanswered questions Translational Cancer Research ·Ana Elisa Lohmann, Kamal S. Saini, Otto Metzger	2012	2
17	The natural history of hormone receptor-positive breast cancer. PubMed ·Elgene Lim, Otto Metzger, Eric P. Winer	2012	107
18	Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer Drug Safety ·Rodrigo Dienstmann, Felipe Ades, Kamal S. Saini, Otto Metzger	2011	8
19	First-line systemic treatment of ovarian cancer: a critical review of available evidence and expectations for future directions Current Opinion in Oncology ·Otto Metzger, Camilo Moulin, Véronique D’Hondt	2010	20
20	Molecular Targeted Therapy in Prevalent Tumors: Learning from the Past and Future Perspectives Current Clinical Pharmacology ·Otto Metzger, Camilo Moulin, Ahmad Awada	2010	10

About Otto Metzger

Otto Metzger is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging, having authored 117 papers that have together received 4.8k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (55 papers), HER2/EGFR in Cancer Research (51 papers), Advanced Breast Cancer Therapies (32 papers), Cancer Treatment and Pharmacology (27 papers), Breast Lesions and Carcinomas (18 papers), Monoclonal and Polyclonal Antibodies Research (12 papers), Estrogen and related hormone effects (10 papers) and Peptidase Inhibition and Analysis (9 papers). The work is most often cited by research in Oncology (3.2k citations), Cancer Research (1.7k citations), Pulmonary and Respiratory Medicine (1.4k citations), Pathology and Forensic Medicine (529 citations) and Genetics (278 citations). Otto Metzger has collaborated with scholars based in United States, Belgium and Italy. Frequent co-authors include Eric P. Winer, Evandro de Azambuja, Martine Piccart, Kamal S. Saini, Ian E. Krop, Sherene Loi, Giuseppe Viale, Michail Ignatiadis, Richard D. Gelber and Jean J. Zhao. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Breast Cancer Research and Treatment and The Breast.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact